Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer

摘要: BACKGROUND: We investigated the risk of central nervous system (CNS) failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in Korean patients nonsmall-cell lung cancer (NSCLC) METHODS: We retrospectively evaluated pattern disease progression 287 advanced NSCLC who were treated gefitinib or erlotinib. Patients whose best tumor response was complete response, partial stable (≥90 days) classified into group receiving these drugs. RESULTS: The had a higher incidence CNS as an initial progression, compared non-clinical (26% vs 4%; P < .001). Isolated also more frequent than (13% 1%; In multivariate analysis, EGFR-TKIs significantly increased isolated failure, adjusted hazard ratio 10.9 (95% confidence interval [CI], 1.4-29.1, = .01). median time from intracranial to extracranial 9.9 months CI, 1.9-21.9 months) and death 12.9 3.3-22.5 months). CONCLUSIONS: The frequently site patients. showed durable control cranial progression. A role for close surveillance during EGFR-TKI treatment prophylactic measures appears worthy further study Cancer 2010. © 2010 American Society.